Clinical trials: Apatinib
Gastric Cancer
A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer
The prognosis of Extensive lymph nodes metastatic(ELM) gastric cancer is poor. Chemotherapy occasionally converts it to a resectable cancer.
- Trial name
- NCT03258034
- Testing
- SPA
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Renal Cell Carcinoma
Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma
This trial will explore effectiveness and safety using the combination therapy of camrelizumab，apatinib and hyperfractionated radiotherapy in patients with renal cell carcinoma(RCC).
- Trial name
- NCT04609293
- Testing
- camrelizumab+apatinib+hyperfractionated radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Intrahepatic Cholangiocarcinoma
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
- Trial name
- NCT03521219
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Physicians Choice Chemotherapy, as treatment, in patients with a Germline BRCA…
- Trial name
- NCT04296370
- Testing
- Fluzoparib; Apatinib, Fluzoparib, Physician's choice chemotherapy
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.
- Trial name
- NCT04781686
- Testing
- Camrelizumab, Apatinib Mesylate, S1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhou Fuxiang
Solid Tumor
Camrelizumab Combined With Apatinib Mesylate
The purpose of this study is to observe the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors
- Trial name
- NCT05380986
- Testing
- Camrelizumab combined with apatinib mesylate
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer Limited Stage
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer.
- Trial name
- NCT06483282
- Testing
- Adebrelimab, Apatinib Mesylate, Etoposide
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jin Ying
Stage IV Cancer
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
The tolerability of apatinib, an effective antiangiogenic agent, varies greatly in patients with stage IV cancer during treatment.
- Trial name
- NCT03475589
- Testing
- apatinib
- Where
- China
- Volunteers
- 217 people
- Sponsor
- Sun Yat-sen University
Esophageal Neoplasms
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
- Trial name
- NCT03787251
- Testing
- Apatinib, The chemotherapeutic drug chosen by the investigator.
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatocellular Carcinoma
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03722875
- Testing
- SHR-1210, apatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Differentiated Thyroid Cancer
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a great challenge in the treatment of thyroid cancer. Tyrosine kinase inhibitors (TKIs), like sorafenib and lenvatinib which have been approved by food and…
- Trial name
- NCT03048877
- Testing
- Apatinib Oral Tablet
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Peking Union Medical College Hospital
Sarcoma
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
This study will evaluate the safety and preliminary efficacy of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in combination with Apatinib and/or Camrelizumab in patients with advanced bone and soft-tissue sarcoma.
- Trial name
- NCT04074564
- Testing
- MASCT-I, Camrelizumab,Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- HRYZ Biotech Co.
Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed…
- Trial name
- NCT04826406
- Testing
- Camrelizumab combined Apatinib regimen
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hunan Cancer Hospital
Esophageal Cancer
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial（IIT).
- Trial name
- NCT03671265
- Testing
- SHR-1210, IMRT or VMAT, Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer
This is a study of Camrelizumab combined with Apatinib versus Apatinib alone in the third-line treatment of metastatic gastric cancer.
- Trial name
- NCT05342389
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Adenoid Cystic Carcinoma
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
It is a randomized phase II study to determine the efficacy and safety of particle therapy with or without apatinib as induction therapy for the treatment of head and neck adenoid cystic carcinoma.
- Trial name
- NCT02942693
- Testing
- Apatinib, Particle Therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Solid Tumor
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.
- Trial name
- NCT04569916
- Testing
- radiotherapy, irinotecan liposome, apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lung Cancer
The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy
The combination of Apatinib and Camrelizumab for progressed NSCLC patients with muti-line therapy : a phaseⅠB clinical study. Brief Summary: Immunotherapy has made a major progress in Lung cancer.However, challenges such as…
- Trial name
- NCT04782622
- Testing
- Apatinib+Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06385873
- Testing
- RC48, Adebrelimab, Apatinib
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Small Cell Lung Carcinoma
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
This single-arm, Phase II study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) combination with Apatinib in participants with ES-SCLC who was response or stable…
- Trial name
- CAMERA (NCT04901754)
- Testing
- Camrelizumab Plus Apatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Henan Cancer Hospital